Xagena.net - Update in Medicine

Update on results from MOVe-OUT Study of Molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19

Merck ( MSD ) and Ridgeback Biotherapeutics have provided an update on the MOVe-OUT study of Molnupiravir ( MK-4482, EIDD-2801 ), an investigational oral antiviral medicine for COVID-19. Data are no ... read article

Neoadjuvant Nivolumab plus chemotherapy has significantly improved event-free survival in patients with resectable non-small cell lung cancer in CheckMate -816

The phase 3 CheckMate -816 trial has met the primary endpoint of improved event-free survival ( EFS ) in patients with resectable stage IB to IIIA non-small cell lung cancer ( NSCLC ). In a prespe ... read article

Chronic heart failure in adult patients with reduced ejection fraction : Verquvo approved in the European Union

The European Commission ( EC ) has granted marketing authorization in the European Union ( EU ) for soluble guanylate cyclase ( sGC ) stimulator Verquvo ( Vericiguat ). In the EU, Verquvo ( 2.5 mg, ... read article

Zynlonta for large B-cell lymphoma, FDA has granted accelerated approval

The Food and Drug Administration ( FDA ) has granted accelerated approval to Zynlonta ( Loncastuximab tesirine-lpyl; Loncastuximab tesirine ), a CD19-directed antibody and alkylating agent conjugate, ... read article

Kerendia to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes - Approved by FDA

FDA has approved Kerendia ( Finerenone ) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in ... read article

FDA has approved Lumakras, the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer

The U.S. Food and Drug Administration ( FDA ) has approved Lumakras ( Sotorasib ) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer ( ... read article

Darzalex Faspro for newly diagnosed light chain amyloidosis, accelerated approval by FDA

The FDA ( Food and Drug Administration ) has granted accelerated approval to Darzalex Faspro ( Daratumumab plus hyaluronidase ) in combination with Bortezomib, Cyclophosphamide and Dexamethasone for n ... read article

FDA has approved Libtayo for non-small cell lung cancer with high PD-L1 expression

The Food and Drug Administration ( FDA ) has approved Libtayo ( Cemiplimab-rwlc, Cemiplimab ) for the first-line treatment of patients with advanced non-small cell lung cancer ( NSCLC ) ( locally adva ... read article

European Union: Keytruda, an anti-PD-1 therapy, approved for metastatic microsatellite instability-high colorectal cancer patients

The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability ... read article

FDA has approved Verquvo for patients with symptomatic chronic heart failure

The U.S. Food and Drug Administration ( FDA ) has approved soluble guanylate cyclase ( sGC ) stimulator Vericiguat under the brand name Verquvo. Vericiguat 2.5 mg, 5 mg, and 10 mg is indicated to re ... read article

Donanemab slows clinical decline of Alzheimer's disease

Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patient ... read article

FDA has approved Onureg for acute myeloid leukemia

The FDA ( Food and Drug Administration ) has approved Azacitidine tablets ( Onureg ) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission ( CR ) or com ... read article

FDA has approved Alunbrig for ALK-positive metastatic non-small cell lung cancer

The FDA ( Food and Drug Administration ) has approved Alunbrig ( Brigatinib ) for adult patients with anaplastic lymphoma kinase ( ALK )-positive metastatic non-small cell lung cancer ( NSCLC ) as det ... read article

ACTT-2 trial: Baricitinib has significant effect on recovery time in COVID-19 patients requiring Oxygen

Baricitinib in combination with Remdesivir has reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with Remdesivir. This finding was part of additio ... read article

CheckMate -649: overall survival and progression-free survival was superior with Nivolumab plus chemotherapy versus chemotherapy in first-line treatment of gastric and esophageal cancers

CheckMate -649, a pivotal phase 3 trial evaluating Nivolumab ( Opdivo ) plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junct ... read article